CONFERENCE HIGHLIGHTS |
|
In yesterday’s pipeline update, Chris Peterson, PharmD, a director in the Emerging Therapeutics department at Express Scripts, reviewed the trend in FDA approvals and noted several of the key therapeutic areas with recent generics. Read more |
|
Launched in December 2012, the NCCN Biomarkers Compendium contains information designed to support decision-making around the use of biomarker, or molecular, testing in patients with cancer. It was the headliner for a presentation by five oncology experts in Session 310. Read more |
|
Consumers who are at high risk for opioid abuse had significantly higher total medical costs ($19,513 vs $5,493) than those who were not at high risk, according to a study by Prime Therapeutics.
Read more |
|
Edith Rosato, CEO of AMCP, talks about the formulary of the future in this exclusive video interview with Managed Healthcare Executive.
Watch now |
|
|
